Money is flowing into cannabis equities at a pace the sector hasn't seen in years, and the AdvisorShares Pure US Cannabis ETF (MSOS) is the clearest gauge of it. The fund posted a 103.7% one-year net asset value return through May 31, dwarfing the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8% return over the same stretch. With $1.13 billion in assets as of June 5 and a 28% run over the past three months alone, MSOS has become the vehicle institutional and retail traders are using to bet on federal cannabis reform actually landing this time.

The catalyst is twofold. Trulieve Cannabis - MSOS' largest holding at roughly 30% of the portfolio - began trading on the NYSE under the ticker TRLV this week, a listing CEO Kim Rivers called a "historic milestone." That kind of senior-exchange access matters far beyond stock-price optics; it changes how a multi-state operator raises capital, negotiates debt, and plans real estate expansion. But listings and share prices are the visible part of the story. Underneath it, the operational backbone of this industry still runs on state-specific compliance infrastructure - seed-to-sale tracking, METRC reporting, and point-of-sale systems built to handle excise tax calculations that vary by jurisdiction. Operators expanding into new medical or adult-use markets, including those relying on compliant cannabis POS in New Jersey, know that back-of-house systems, not headlines, determine whether a rescheduling win actually reaches the bottom line. compliant cannabis POS in New Jersey

Why the Schedule III Hearing Carries Weight

The June 29 administrative hearing will examine whether cannabis products broadly - not just state-licensed medical marijuana - should move to Schedule III. That distinction matters enormously for operators still boxed in by Section 280E of the federal tax code, which bars businesses trafficking in Schedule I or II substances from deducting ordinary expenses like payroll, rent, and marketing. Acting Attorney General Todd Blanche's April move already shifted state-licensed medical marijuana into Schedule III, eliminating those tax penalties for medical-only operators. A broader rescheduling covering adult-use cannabis would extend that relief across the industry - meaningfully improving free cash flow for companies that have spent years absorbing effective tax rates far above what other retailers pay.

Uplisting Is the Quiet Prize

Beyond taxation, rescheduling opens a door multi-state operators have wanted open for a long time: access to U.S. capital markets, institutional investors, and traditional banking relationships. Cresco Labs' new $50 million revolving credit facility from Needham Bank is an early sign of what that access looks like in practice - non-dilutive financing that CEO Charlie Bachtell says positions the company for a future senior-exchange uplisting. Roth Capital called the rescheduling order "extremely favorable," citing benefits for capital access and overall sector investability. Fair enough - but uplisting requires more than regulatory clearance. It demands audited financials, governance standards, and operational discipline that some operators, still managing budroom inventory and compliance logs built for a cash-heavy, state-siloed business, haven't fully built out yet.

Reading the Upside Numbers Carefully

Analyst price targets embedded in MSOS holdings tell an uneven story. Verano carries the steepest implied upside at 195%, followed by Jushi Holdings at 183% and Cresco Labs near 99%. Green Thumb Industries, at 70% upside, outpaces both Trulieve and Curaleaf - the world's largest cannabis company by revenue - despite trading with less fanfare. Glass House Brands is the outlier with a projected 22% downside, a reminder that not every operator benefits equally from a reform narrative. Retail sentiment on platforms like Stocktwits runs "extremely bullish" on MSOS, Trulieve, and Green Thumb, but enthusiasm on social channels is not the same as regulatory certainty. The hearing could run through mid-July, and administrative proceedings of this kind rarely move on the timeline traders hope for.

What Operators Should Watch Next

• Whether the June 29 hearing produces a firm rescheduling timeline or further procedural delay
• How 280E relief, if extended to adult-use operators, changes wholesale pricing and reinvestment decisions
• Which multi-state operators have the audited financials and compliance infrastructure needed to pursue a senior-exchange uplisting
• How improved capital access affects lab testing, COA transparency, and compliant packaging investment across the supply chain

None of this changes the fact that cannabis remains a state-regulated, federally constrained business with real consumer-safety obligations - age verification, lab-tested product batches, and marketing restrictions chief among them. A stock rally driven by regulatory anticipation is not the same as regulatory reality. Operators and investors alike would do well to remember the difference before the hearing even starts.